Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• Nintedanib demonstrated effectiveness in slowing the progression of interstitial lung disease (ILD) across multiple types, including idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD (SSc-ILD), rheumatoid arthritis-associated ILD (RA-ILD), and connective tissue disease-associated ILD (CTD-ILD), by reducing the rate of forced vital capacity (FVC) decline.
• In IPF, nintedanib and pirfenidone were both effective in decreasing FVC decline, with meta-analyses confirming nintedanib’s consistent role in lung function preservation. Both drugs displayed similar efficacy for IPF, while in RA-ILD, nintedanib showed a significant reduction in FVC decline compared to placebo.
• In subgroup analyses, nintedanib’s benefits extended to various ILD subtypes, including usual interstitial pneumonia (UIP) and non-UIP patterns, and across demographic variables such as age, gender, and ethnicity in IPF patients, with some variability in response observed among subtypes like fibrotic hypersensitivity pneumonitis and fibrotic sarcoidosis.
• Nintedanib treatment in interstitial lung disease (ILD) commonly led to gastrointestinal side effects, including diarrhea, nausea, vomiting, and weight loss, with a higher rate of these events resulting in treatment discontinuation compared to placebo.
• Severe adverse events were not significantly more frequent with nintedanib than with placebo, and fatal adverse events were also comparable between treatment and placebo groups.
• There is no population type or subgroup information available in the reviewed studies.